Pulse Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on May 9, 2023. The report details the consummation of a private placement transaction previously announced on May 1, 2023.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial data disclosed relates to a specific equity transaction:
- Shares Issued: 10,022,937 shares of common stock.
- Purchase Price: $6.51 per share.
- Premium: Greater than 1% over the last closing price of $6.44 per share on April 28, 2023.
- Total Proceeds: Approximately $65.16 million (calculated as 10,022,937 shares * $6.51).
Material Changes
The material change reported is the completion of a Securities Purchase Agreement dated April 30, 2023. The buyer was Robert W. Duggan, the Company's Executive Chairman of the Board of Directors and majority stockholder. This transaction resulted in an increase in the Company's outstanding common stock and cash assets.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factors beyond the standard disclosure of the transaction terms. The transaction was executed as a private placement under unregistered sales of equity securities.
Key Facts for Investor Verification
- Verify the total cash proceeds received from the sale of 10,022,937 shares at $6.51 per share.
- Confirm the updated share count and the dilution impact on existing shareholders.
- Review the May 1, 2023 Form 8-K for the full terms of the Securities Purchase Agreement.
- Assess the strategic intent of the Executive Chairman purchasing a significant block of shares at a premium to the market price.